Specific Mutations Identified in Patients Vaccinated and Infected with COVID-19 in Senegal
Article Sidebar
Downloads
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
Abstract
Background: Vaccination against SARS-CoV-2 is currently the best preventive measure to control the COVID-19 pandemic. However, in some cases, it appeared that despite the vaccination, some people were reinfected.
Aim: The objective of this study is to monitor preliminary data of COVID-19 reinfection cases in vaccinated individuals in Senegal.
Methods: In this study, we used the Oxford Nanopore MinION portable sequencer as detailed in the ARTIC network to test SARS-CoV-2 positive samples from reinfected patients. A total of 71 subjects were monitored with 37 vaccinated patients and 34 non-vaccinated and samples were sequenced in genomic platform at IRESSEF.
Results: We noted the presence of three major lineages B.1.617.2, AY4 and AY34 in vaccinated people. In addition, the mutation W152R and two other mutations never described (T1136S and V1137L) were found in tested genomic sequences.
Conclusion: These results will contribute to monitor future epidemics and to control the effectiveness of the vaccination against COVID-19 especially the Variant of Concern and allow us to improve surveillance for COVID-19 pandemic.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Episode #64 - Why are experts concerned about Omicron? Accessed July 17, 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5/episode-64---why-are-experts-concerned-about-omicron
3. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Published online December 22, 2020:2020.12.21.20248640. doi:10.1101/2020.12.21.20248640
4. Padane A, Kanteh A, Leye N, et al. First detection of SARS-CoV-2 variant B.1.1.7 in Senegal. New Microbes New Infect. 2021;41:100877. doi:10.1016/j.nmni.2021.100877
5. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Published online July 23, 2021:2021.07.07.21260122. doi:10.1101/2021.07.07.21260122
6. Christensen PA, Olsen RJ, Long SW, et al. Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. Am J Pathol. 2022;192(2):320-331. doi:10.1016/j.ajpath.2021.10.019
7. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(31):1059-1062. doi:10.15585/mmwr.mm7031e2
8. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021;384(23):2212-2218. doi:10.1056/NEJMoa2105000
9. Singh UB, Rophina M, Chaudhry R, et al. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India. Journal of Medical Virology. 2022;94(4):1696-1700. doi:10.1002/jmv.27461
10. Prévost J, Finzi A. The great escape? SARS-CoV-2 variants evading neutralizing responses. Cell Host Microbe. 2021;29(3):322-324. doi:10.1016/j.chom.2021.02.010
11. Augusto G, Mohsen MO, Zinkhan S, Liu X, Vogel M, Bachmann MF. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. Allergy. 2022;77(1):111-117. doi:10.1111/all.15065
12. Diédhiou CK, Padane A, Gueye K, et al. Heterogeneity of the Omicron variant in Senegal. New Microbes and New Infections. 2022;47. doi:10.1016/j.nmni.2022.100990
13. Padane A, Kanteh A, Leye N, et al. First detection of SARS-CoV-2 variant B.1.1.7 in Senegal. New Microbes New Infect. 2021;41:100877. doi:10.1016/j.nmni.2021.100877
14. Padane A, Diedhiou CK, Gueye K, et al. Dynamics of Variants of Concern (VOC) of SARS-CoV-2 during the Different Waves of COVID-19 in Senegal. COVID. 2022;2(6):691-702. doi:10.3390/covid2060052
15. Gueye K, Padane A, Diédhiou CK, et al. Evolution of SARS-CoV-2 Strains in Senegal: From a Wild Wuhan Strain to the Omicron Variant. COVID. 2022;2(8):1116-1124. doi:10.3390/covid2080082
16. Min L, Sun Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. Frontiers in Molecular Biosciences. 2021;8. Accessed July 17, 2023. https://www.frontiersin.org/articles/10.3389/fmolb.2021.671633
17. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection. 2022;28(2):202-221. doi:10.1016/j.cmi.2021.10.005
18. Diarra M, Kebir A, Talla C, et al. Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study. BMJ Global Health. 2022;7(2):e007236. doi:10.1136/bmjgh-2021-007236
19. About 300,000 additional doses of Covid-19 vaccines for Senegal. Accessed September 15, 2023. https://www.unicef.org/senegal/en/press-releases/about-300000-additional-doses-covid-19-vaccines-senegal
20. Réseau arctique. Accessed July 17, 2023. https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html
21. Nextclade. Accessed July 17, 2023. https://clades.nextstrain.org
22. COG-UK. Accessed July 17, 2023. https://pangolin.cog-uk.io/
23. Re3data.Org. GISAID. Published online 2012. doi:10.17616/R3Q59F
24. Mutations CoV-GLUE. Accessed July 17, 2023. https://cov-glue.cvr.gla.ac.uk/mutations.php?lineage=B.1.487
25. Musser JM, Christensen PA, Olsen RJ, et al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. Published online 2021. Accessed July 17, 2023. https://medrxiv.org/cgi/content/short/2021.07.19.21260808
26. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar. Published online March 22, 2022:2022.03.22.22272745. doi:10.1101/2022.03.22.22272745
27. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv. Published online August 21, 2021:2021. 08.06.21261707. doi:10.1101/2021.08.06.21261707
28. Thangaraj JWV, Yadav P, Kumar CG, et al. Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021. Journal of Infection. 2022;84(1):94-118. doi:10.1016/j.jinf.2021.08.006
29. MINISTÈRE DE LA SANTÉ ET DE L’ACTION SOCIALE |. Accessed July 17, 2023. https://www.sante.gouv.sn/